Ten-year Medicare budget impact of increased coverage for anti-obesity intervention

References

• Tremmel M, Gerdtham UG, Nilsson PM, et al. Economic burden of obesity: a systematic literature review. Int.J.Environ.Res.Public Health. 2017;14:E435.
   PubMed Web of Science ®Google Scholar
• Li Q, Blume SW, Huang JC, et al. The economic burden of obesity by glycemic stage in the United States. Pharmacoeconomics. 2015;33:735–748.
   PubMed Web of Science ®Google Scholar
• Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815–825.
   PubMed Web of Science ®Google Scholar
• Milken Institute. Weighting down America: the health and economic impact of obesity. 2016 November [cited 2018 Mar 19]. Available from: https://www.milkeninstitute.org/reports/weighing-down-americahealth-and-economic-impact-obesity
   Google Scholar
• US Census Bureau. National Population Projections 2018 Sep 6. 2017 [cited 2019 Feb 13]. Available from: https://www.census.gov/programs-surveys/popproj.html.
   Google Scholar
• Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–2291.
   PubMed Web of Science ®Google Scholar
• Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5–13.
   PubMed Web of Science ®Google Scholar
• Ali MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program?. Health Aff (Millwood). 2012;31:67–75.
   PubMed Web of Science ®Google Scholar
• Dall TM, Storm MV, Semilla AP, et al. Value of lifestyle intervention to prevent diabetes and sequelae. Am J Prev Med. 2015;48:271–280.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Astrup A, Fujioka K, et al. 3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–1409.
   PubMed Web of Science ®Google Scholar
• Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med. 2014;126:7–18.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–120.
   PubMed Web of Science ®Google Scholar
• Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013;6:131–139.
   PubMedGoogle Scholar
• Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74–86.
   PubMed Web of Science ®Google Scholar
• Cabrerizo GL, Ramos-Levi A, Moreno LC, et al. Update on pharmacology of obesity: benefits and risks. Nutr Hosp. 2013;28:121–127.
   PubMed Web of Science ®Google Scholar
• Intensive Behavioral Therapy (IBT) for Obesity. The Centers for Medicare and Medicaid Services. Final Coverage Decision Memorandum for Intensive Behavioral Therapy for Obesity. 2012 Mar 9 [cited 2019 Feb 13]. Available from: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&NcaName=Intensive%20Behavioral%20Therapy%20for%20Obesity&bc=ACAAAAAAIAAA&NCAId=253.
   Google Scholar
• Noelia D, Eamon M, Lori H, et al. Estimating the effects of federal policies targeting obesity: challenges and research needs. CBo Blog. 2015 Oct 26 [cited 2018 Mar 14]. Available from: https://www.cbo.gov/publication/50877.
   Google Scholar
• The Treat and Reduce Obesity Act of 2017 (S.830/H.R.1953). 2017 Apr 5 [cited 2019 Feb 13]. Available from: https://www.congress.gov/bill/115th-congress/house-bill/1953.
   Google Scholar
• Chen F, Su W, Becker SH, et al. Clinical and economic impact of a digital, remotely-delivered intensive behavioral counseling program on medicare beneficiaries at risk for diabetes and cardiovascular disease. PLoS One. 2016;11:e0163627.
   PubMed Web of Science ®Google Scholar
• Su W, Huang J, Chen F, et al. L. Modeling the clinical and economic implications of obesity using microsimulation. J. Med. Econ. 2015;18:886–897.
   PubMed Web of Science ®Google Scholar
• Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898–904.
   PubMed Web of Science ®Google Scholar
• Semilla AP, Chen F, Dall TM. Reductions in mortality among Medicare beneficiaries following the implementation of Medicare Part D. Am J Manag Care. 2015; 21:s165–s171.
   PubMed Web of Science ®Google Scholar
• Felix HC, West DS. Effectiveness of weight loss interventions for obese older adults. Am J Health Promot. 2013;27:191–199.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161.
   PubMed Web of Science ®Google Scholar
• Anastasiou CA, Karfopoulou E, Yannakoulia M. Weight regaining: from statistics and behaviors to physiology and metabolism. Metab Clin Exp. 2015;64:1395–1407.
   PubMed Web of Science ®Google Scholar
• Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299–1307.
   PubMed Web of Science ®Google Scholar
• Joyce GF, Escarce JJ, Solomon MD, et al. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733–1739.
   PubMed Web of Science ®Google Scholar
• Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–1229.
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. JMCP. 2009;15:728–740.
   PubMed Web of Science ®Google Scholar
• Vrijens B, Antoniou S, Burnier M, et al. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Crouse WL, Zhuo X, et al. Medicare's intensive behavioral therapy for obesity: an exploratory cost-effectiveness analysis. Am J Prev Med. 2015;48:419–425.
   PubMed Web of Science ®Google Scholar
• Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018;7:147–161.
   PubMed Web of Science ®Google Scholar
• O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–649.
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–2193.
   PubMed Web of Science ®Google Scholar
• The Medicare Payment Advisory Commission. Report to the Congress: Medicare and the Health Care Delivery System. Washington, DC; 2017 Jun 15.
   Google Scholar
• Thorpe KE, Yang Z, Long KM, et al. The impact of weight loss among seniors on Medicare spending. Health Econ Rev. 2013;3:7.
   PubMedGoogle Scholar
• Kaiser Family Foundation. Medicare spending at the end of life: a snapshot of beneficiaries who died in 2014 and the cost of their care. 2016 Jul 14 [cited 2018 Mar 23]. Available from https://www.kff.org/medicare/issue-brief/medicare-spending-at-theend-of-life/
   Google Scholar
• Domenica MR, Scott K, Robert FK. Age no impediment to effective weight loss with liraglutide 3.0 mg: data from two randomized trials. Conference: XXI I Congresso Brasileiro de Nutrologia; 2017.
   Google Scholar